Toggle Main Menu Toggle Search

Open Access padlockePrints


Lookup NU author(s): Professor Matthew CollinORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2021 Elsevier LtdHistiocytoses constitute a heterogeneous group of rare disorders, characterised by infiltration of almost any organ by myeloid cells with diverse macrophage or dendritic cell phenotypes. Histiocytoses can start at any age. Diagnosis is based on histology in combination with appropriate clinical and radiological findings. The low incidence and broad spectrum of clinical manifestations often leads to diagnostic delay, especially for adults. In most cases, biopsy specimens infiltrated by histiocytes have somatic mutations in genes activating the MAP kinase cell-signalling pathway. These mutations might also be present in blood cells and haematopoietic progenitors of patients with multisystem disease. A comprehensive range of investigations and molecular typing are essential to accurately predict prognosis, which can vary from spontaneous resolution to life-threatening disseminated disease. Targeted therapies with BRAF or MEK inhibitors have revolutionised salvage treatment. However, the type and duration of treatment are still debated, and the prevention of neurological sequelae remains a crucial issue.

Publication metadata

Author(s): Emile J-F, Cohen-Aubart F, Collin M, Fraitag S, Idbaih A, Abdel-Wahab O, Rollins BJ, Donadieu J, Haroche J

Publication type: Review

Publication status: Published

Journal: The Lancet

Year: 2021

Volume: 398

Issue: 10295

Pages: 157-170

Print publication date: 10/07/2021

Online publication date: 23/04/2021

Acceptance date: 02/04/2018

ISSN (print): 0140-6736

ISSN (electronic): 1474-547X

Publisher: Elsevier B.V.


DOI: 10.1016/S0140-6736(21)00311-1

PubMed id: 33901419